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MEETING REPORT
Fake anti-malarials: start with the facts
Harparkash Kaur1*, Siȃn Clarke1, Mirza Lalani1, Souly Phanouvong2, Philippe Guérin3,4, Andrew McLoughlin5, 
Benjamin K. Wilson6, Michael Deats7, Aline Plançon8, Heidi Hopkins1, Debora Miranda1 
and David Schellenberg1
Abstract 
This meeting report presents the key findings and discussion points of a 1-day meeting entitled ‘Fake anti-malarials: 
start with the facts’ held on 28th May 2015, in Geneva, Switzerland, to disseminate the findings of the artemisinin 
combination therapy consortium’s drug quality programme. The teams purchased over 10,000 samples, using rep-
resentative sampling approaches, from six malaria endemic countries: Equatorial Guinea (Bioko Island), Cambodia, 
Ghana, Nigeria, Rwanda and Tanzania. Laboratory analyses of these samples showed that falsified anti-malarials (<8 %) 
were found in just two of the countries, whilst substandard artemisinin-based combinations were present in all six 
countries and, artemisinin-based monotherapy tablets are still available in some places despite the fact that the WHO 
has urged regulatory authorities in malaria-endemic countries to take measures to halt the production and marketing 
of these oral monotherapies since 2007. This report summarizes the presentations that reviewed the public health 
impact of falsified and substandard drugs, sampling strategies, techniques for drug quality analysis, approaches to 
strengthen health systems capacity for the surveillance of drug quality, and the ensuing discussion points from the 
dissemination meeting.
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Background
Artemisinin-based combination therapy (ACT) is rec-
ommended as first line treatment for malaria treatment 
by the World Health Organization (WHO) and effective 
malaria treatment requires the use of good quality medi-
cation [1]. Poor quality medications may result in need-
less morbidity and mortality and can facilitate emergence 
of drug resistance [2]. Reports of various surveys from 
South East Asia showed that up to 50 % of the artesunate 
monotherapy sold was fake and the situation was envis-
aged to get worse in malaria endemic countries, with the 
implementation of the ACT, which is more expensive [3–
6]. Low and middle-income malaria endemic countries 
are prone to a number of risk factors for poor quality 
ACT. Primarily these include ineffectual drug regula-
tion and inadequate technical capacity, which are com-
pounded by a lack of political will and resources [7].
Medicines quality is divided into four main classes; 
quality assured; falsified (counterfeit); substandard; or 
degraded. But there are no universally-accepted defini-
tions of these categories [8]. Quality-assured medicines 
have the acceptable amount of active pharmaceutical 
ingredients as specified by the pharmacopeia’s and meet 
other quality attributes; falsified medicines do not con-
tain the stated active pharmaceutical ingredient (SAPI) 
and may carry false representation of their source of 
identity. A falsified drug could signal a potential coun-
terfeit product, which does not comply with intellectual 
property rights or may infringe trademark law [9]. Sub-
standard drugs are produced with inadequate attention 
to good manufacturing practices and may have contents 
or dissolution times that are outside accepted limits, due 
to poor quality control [10, 11]. Degraded formulations 
may result from exposure of good-quality medicines to 
light, heat, and humidity. It can be difficult to distinguish 
degraded medicines from those that left the factory as 
substandard, but the distinction is important because the 
causes and remedies will be different.
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Purpose of the meeting
The ACT Consortium drug quality programme (ACTc-
DQP) held a meeting in Geneva, Switzerland, and 
shared findings from their multi-country study that 
assessed the quality of over 10,000 artemisinin-based 
combinations, purchased in six malaria endemic coun-
tries. The meeting was attended by 34 representa-
tives from 20 institutions, including the World Health 
Organization (WHO), United States Pharmacopeia 
(USP), the Global Fund (GF), INTERPOL as well as 
other academic institutions. Participants included poli-
cymakers, programme managers, researchers, technical 
advisors and donors.
David Schellenberg, director of the ACT Consortium, 
opened the meeting, citing earlier reports that as many as 
a third of anti-malarials are ‘fake’ [12–14]. Such reports 
formed the rationale for the ACT Consortium drug qual-
ity programme to investigate the quality of artemisinin-
based combinations at a larger scale than in previous 
studies; using a representative sampling approach and 
standardized methodology to assess the prevalence of 
fake and substandard artemisinin-based combinations 
across a range of countries in sub-Saharan Africa. The 
aim was to provide Ministries of Health with the evi-
dence upon which local regulators can take action.
Public health impact: a focus on drug quality
The public health impact of poor quality ACT is stark. 
The focus is often on falsified drugs, and the direct dan-
gers for the patient i.e. delayed clinical recovery and 
increased mortality. However, a further public health 
concern is the potential indirect impact, through the 
promulgation of drug resistance due to substandard 
anti-malarials.
To counter this threat requires routine surveillance sys-
tems and technical capacity to monitor drug quality on an 
ongoing basis, supported by effective regulatory action at 
national and international level. Souly Phanouvong, sen-
ior manager, Asia programmes, USP started the meeting 
and his presentation set the scene by outlining the tech-
nical, coordination, capacity and operational challenges 
they had encountered during monitoring drug quality in 
the Mekong sub-region. Contributing factors to problems 
with medicine quality were identified as weak institu-
tional capacity that does not ensure good quality medi-
cines are produced, procured, supplied and distributed 
to patients. There remains a need to strengthen surveil-
lance, build capacity in country by ensuring that national 
quality control laboratoriess are sufficiently equipped to 
carry out the work. Once data is generated it needs to 
be shared in a timely manner which needs people with 
experience for the task. Added to the effort is the need to 
identify the key suppliers, manufacturers and distributors 
of poor quality drugs and have the regulatory capacity in 
place at the national level to root out the problem.
Status of ACT quality
Establishing the scale of the problem of poor quality ACT 
remains a challenge. The WWARN Antimalarial Qual-
ity Surveyor Database (AQSD) was created to collate and 
present a comprehensive overview of the quality of anti-
malarials, incorporating reports from both the scientific 
and grey literature [15]. It includes studies on anti-malarial 
drug quality spanning the past 67 years and indicates that 
around 30 % of anti-malarials tested have not met the cri-
teria for good quality drugs, containing the acceptable 
amount of SAPI [16]. However, comparison of drug quality 
findings across time and place is hampered by methodo-
logical differences in the sampling strategies and laboratory 
techniques used in different studies. In some cases, it is not 
clear whether the samples examined were representative of 
all anti-malarial drugs on the market. Geographical dispari-
ties have also been found in the data available. This is espe-
cially the case in sub-Saharan Africa where the overview of 
anti-malarial drug quality is dominated by data from three 
countries—Nigeria, Tanzania and Ghana.
Sampling strategies
An epidemiologist’s perspective was presented by Siȃn 
Clarke of the ACTc, on the challenge of assessing the 
extent of the ACT quality problem. She focused on sam-
pling strategies to collect drugs, including their advan-
tages and disadvantages (Table 1), illustrated by an analysis 
of the data points included in the AQSD during the last 
5  years (2010–2015). The majority of reports, scientific 
studies and national drug quality surveys from Africa used 
a convenience sampling approach. This is a type of non-
random sampling in which surveyors may sample drugs 
from outlets based primarily on ease of access or perceived 
risk [17]. Purposive and convenience approaches are effi-
cient and cost-effective, but are more likely to be flawed by 
selection bias. Indeed, if the AQSD data points are com-
pared according to the sampling method that was used, 
the proportion of medicines that fail testing was generally 
higher in studies that used convenience sampling than in 
studies that used random sampling. Random sampling 
should yield a more representative estimate of prevalence, 
provided the sampling frame (list of outlets) is compre-
hensive and up-to-date. The reliability and generalizability 
should be robust and the results can be replicated.
At the outlet, the drug samples to be tested may be pro-
cured using a covert approach (so-called ‘mystery shop-
per’), where the researcher poses as a patient and asks 
for a drug to treat malaria. This has a relatively low risk 
of sampling bias, but the number of brands that can be 
obtained will be limited. An alternative approach is overt 
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sampling in which the researcher informs the outlet staff 
of the purpose of the research and requests drugs, and 
completes a short questionnaire. There is a risk of sam-
pling bias if outlets refuse to be sampled or are aware of 
which samples might be poor quality. The advantage is 
that more samples and additional information, for exam-
ple regarding the supply chain or educational level of the 
provider, can be collected at minimal incremental cost. 
The results can thus provide more detail than the covert 
approach, such as sources of poor quality drugs, but may 
be compromised if sampling bias occurs.
Despite these considerations, results from the ACTc 
studies in Nigeria [18] and Cambodia [19] found that 
there was little difference between the drug samples 
obtained using overt and mystery approaches. However, 
artemisinin monotherapies (marketing for which is now 
prohibited by the WHO for uncomplicated Plasmodium 
falciparum malaria and subject to a national ban on 
sales in some countries) [20] were more readily detected 
through mystery clients than through overt sampling. 
This suggests that the reliability of the sampling approach 
used may also depend on the type of products sampled 
and the local regulatory context.
Techniques for analysing drug quality
A well-equipped medicines quality control labora-
tory (MQCL) is the crucial component of any drug 
quality assurance system; with a range of analytical 
equipment such as high performance liquid chroma-
tography and mass spectrometry systems, as well as 
quality-assured reference standards, all of which is cost 
intensive. An MQCL also requires staff with a high 
level of technical expertise and extensive knowledge of 
method development.
The need for the rapid detection of poor quality drugs 
through the supply chain has seen the development of 
hand held devices, based on spectroscopic methods, for 
use as screening tools. A broad overview of currently 
available technologies was presented by Ben Wilson of 
Intellectual Ventures Laboratory/Global Good. Recent 
advances in such technologies depend on being both 
cost-effective and easy to operate as they use a variety of 
approaches to assess drug quality including; product rec-
ognition, detection of SAPI and composition determina-
tion in the effort to detect the falsified drug.
Product recognition aims to establish whether the pack-
aging is genuine or not. This requires a sample of the origi-
nal manufacturer’s packaging or being familiar with key 
features of the packaging. The technologies being devel-
oped include handheld versions of methods previously used 
only in laboratories, such as mass spectrometry (MS) and 
nuclear magnetic resonance (NMR) [21]. Despite the accu-
racy of these technologies, they are complex to use (espe-
cially in a field setting), requiring specialist skills to operate 
and are cost intensive (around £50,000 per unit) [22].
Two main approaches to detect a SAPI or identify fal-
sified medications were discussed; spectroscopy tech-
niques and separation techniques. The former utilizes 
infrared spectroscopy e.g., the Raman handheld device 
[23], which involves acquiring spectra from a drug blis-
ter and comparing it with a library of spectra from well-
characterized samples. The cost of infrared spectroscopy 
and performance is dependent on the wavelength range 
(broader the range cheaper the price and more defined 
ranges entail greater price). Devices provide purport-
edly fairly accurate results and are straightforward to use 
once the individual has been appropriately trained, how-
ever their capital cost (in the range of $2625–$17,485 for 
a Raman handheld device) may be prohibitive [19]. The 
cost per test is a relative advantage of spectroscopy meth-
ods. Separation techniques such as paper-based chroma-
tography allow the simple testing of multiple SAPIs on 
a single piece of card (known as multiplexing) [20–22]. 
This is very simple to use and inexpensive but is poor at 
SAPI quantitation. Another separation technique Phar-
macheck [23] uses photoluminescence and microfluidics 
Table 1 Comparative strengths and weaknesses of three sampling approaches [18]
Sampling 
approach
Strengths Limitations
Convenience Rapid
Low cost
Sampling depends on collectors choice of outlet (risk of bias)
Poor documentation—findings hard to replicate
Prevalence estimates are not reliable
Random Sampling frame is defined to obtain representative 
sample from all types of outlets and/or brands
Results can be replicated
Need to authenticate and update sampling frame increases time and cost 
of survey
Mystery clients Outlets are unaware of survey so less chance of  
sample bias
Information on sources of poor quality drugs limited to brand, batch and 
country of manufacture as stated on packaging
Overt Additional information is collected at minimal addi-
tional cost to mystery approach as provider is  
aware of the aims of the study
Risk of sampling bias in samples collected, if some outlets refuse to sell or 
samples are deliberately withheld as poor quality is known by the seller
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in place of paper and colour change and purports to 
be quantitative thus enabling detection of substand-
ard drugs. A rapid, semi-quantitative, simple to use and 
low-cost thin layer chromatography-based test that spe-
cifically detects the artemisinin component of ACT, has 
been developed at and patented by London School of 
Hygiene and Tropical Medicine (LSHTM) [24].
Despite a range of screening devices available there 
is as yet a lack of a systematic comparison in terms of 
their cost, performance and ultimately chemical content 
analysis, with methods listed in international pharma-
copeia, such as high performance liquid chromatogra-
phy (HPLC), which measures the quantitative amount of 
SAPI and is regarded as the gold standard [25].
Findings from the ACT Consortium drug quality 
programme
Reports of fake drugs formed the rationale for the ACTc-
DQP to investigate the quality of ACT at a larger scale 
than in previous studies with the aim of providing Minis-
tries of Health with evidence upon which local regulators 
could take action. Harparkash Kaur, the lead investigator 
of the ACTc-DQP presented the findings on behalf of the 
drug quality teams [11]. The ACTc-DQP collected 10,079 
samples from ACT tablets from six countries; Equato-
rial Guinea (Bioko Island), Cambodia, Ghana, Nigeria, 
Rwanda and Tanzania, primarily using random sampling 
and both overt and mystery client approaches, Table  2. 
The samples were processed in the three corroborating 
laboratories as shown in Fig.  1. All sample information 
was logged onto the country specific databases. The sam-
ples from each study were analysed by HPLC at LSHTM, 
UK and a duplicate set was sent to Michael Green’s team 
at the Centre for Disease Control, Georgia, USA, who 
randomly selected ten percent of samples out of the total 
sent and analysed them using HPLC to corroborate the 
results from LSHTM. Additional validation was provided 
by Facundo Fernandez’s team, who analysed a dupli-
cate set of samples using MS at the Georgia Institute of 
Technology, USA to confirm the presence of the stated 
SAPI or the detection of unstated compound instead. 
Laboratory analysis results for each sample were added 
to the database of sample information for each country.
Results from the three laboratories enabled robust esti-
mates of quality and cross-validation demonstrating that 
if the sampling strategy is representative and the analyti-
cal methods are of the highest standard, then findings are 
repeatable and reliable. These are important considera-
tions when an issue is identified with drug quality and it 
becomes necessary to track the impact of efforts made to 
improve drug quality.
The findings from six countries show that the propor-
tion of falsified drugs is much lower than the reported 
‘one third’ in previous studies. The ACTc-DQP team 
tested less than the 20 tablets per sample as stipulated by 
USP, hence they used wider tolerance limits of 85–115 % 
to classify drugs to be of acceptable quality instead of the 
90–110  % given by USP and WHO [26]. The wider tol-
erance limits may underestimate the proportion of sub-
standard drugs but they will not affect the estimates of 
the falsified drugs found. Results from their study pub-
lished the day before the dissemination meeting docu-
mented the quality of ACT from Enugu State, Nigeria 
[18]. Kaur reported that just 1.2 % of 3024 ACT samples 
collected from every known pharmacy, patent medicine 
vendor and public health facility, were falsified (did not 
contain the SAPIs). Furthermore two other published 
ACTc studies from Cambodia and Tanzania detected no 
falsified ACT [19, 27]. However, substandard ACT was 
found in each of the six countries, with as many as 31.3 % 
of 291 samples collected in Cambodia [19] failing to meet 
the tolerance limits (i.e. SAPIs between 85 and 115  %) 
for acceptable quality drugs. The findings demonstrate 
that the threat of substandard drugs is in some instances 
greater than that of falsified drugs and merit more atten-
tion than they have received so far.
The focus in recent years has been on counterfeit or 
falsified drugs, especially anti-malarials, however these 
Table 2 Numbers of samples analysed and quality of ACT found per country
Country (date of sampling) Number 
of samples
Number 
of brands
Percent  
quality assured
Percent  
falsified
Percent  
Substandard
Artemisinin 
monotherapy 
tablets
Rwanda (2008) 97 1 93.8 Not found 6.2 Not found
Cambodia (2010) 291 21 68.7 Not found 31.3 Found
Ghana-Kintampo (2011) 257 31 63.0 Not found 37.0 Not found
Tanzania (2010) 1737 37 88.0 Not found 12.0 Found
Tanzania (2011) 2546 46 97.8 Not found 2.2 Found
Nigeria-Enugu Metropolis (2013) 3024 131 92.2 1.2 6.6 Found
Nigeria-Ilorin city (2013) 1450 77 91.5 0.8 7.7 Found
Equatorial Guinea-Bioko Island (2014) 677 142 91.0 7.4 1.6 Found
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results indicate that the risk of substandard drugs has 
perhaps been understated.
Degraded products
The knowledge base for degraded drugs is sparse at best 
and non-existent for ACT, reported Harparkash Kaur. 
The ACTc-DQP, LSHTM team, also undertook addi-
tional studies to determine the stability of ACT tablets 
and degraded products.
‘Natural ageing’ of 2880 samples each of artemisinin-
based combinations Coartem® (artemether–lumefan-
trine) and ASAQ Winthrop® (artesunate-amodiaquine) 
was undertaken to evaluate their long-term stability in 
tropical climates. Samples were aged in the presence and 
absence of light, on-site in Ghana and in a stability cham-
ber (London), removed from each site at regular intervals 
and analysed to measure loss of the SAPIs over time and, 
detect products of degradation. Loss of SAPIs in samples 
(both in Ghana and the stability chamber), was 0–7  % 
over 3  years (~12  months beyond expiry) with low lev-
els of degradation products detected [28]. In addition, 
none of the degradation products were found to exhibit 
anti-malarial activity. Presence of degradation products 
together with evidence of insufficient APIs can be used to 
classify drugs as degraded.
Drug quality and the emergence of resistance
The impact of substandard drugs is particularly wor-
rying when viewed in the context of drug resistance, 
specifically to artemisinin derivatives [29]. Philippe 
Guérin, Director of the World Wide Antimalarial Resist-
ance Network [WWARN], reported that there are now 
confirmed cases of artemisinin resistance in Cambodia, 
Laos, Thailand and Myanmar. The mechanisms of resist-
ance are complex and not yet fully understood. Poor 
quality ACT is one of many factors that are likely to fuel 
drug resistance, for instance if sub-therapeutic levels of 
SAPIs are included in ACT formulations. However the 
most important driver of artemisinin resistance may be 
the prolonged use (nearly 30  years) in South East Asia 
of artemisinin monotherapy. The gravest concern is the 
spread of resistance beyond South-East Asia and into 
sub-Saharan Africa, which could lead to a potentially 
cataclysmic situation, effectively wiping out a decade 
of investment in malaria control and treatment pro-
grammes [30].
’Has everything been done to prevent or delay the 
evolution of drug resistance. Preventing the global 
spread is not an on-off button, its a complex mecha-
nism. It requires us to recognise the science behind 
drug resistance, which must be translated into 
public health action. It can be achieved by improv-
ing the value of existing data, preserving efficacy of 
drugs in current use, detecting and managing resist-
ance spread/emergence and ensuring efficacy of new 
drugs’.
LSHTM (UK) 
Harparkash Kaur 
 
• Sample informa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Fig. 1 Diagram of sample flow and corroborative analyses at three independent laboratories
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Strengthening drug quality surveillance 
and regulation
Presentations by USP, WHO and Interpol reflected on 
progress with ongoing initiatives to strengthen the capac-
ity of national and international networks to monitor 
drug quality. The USP Promoting the Quality of Medi-
cines programme [31] in part seeks to strengthen regula-
tory, technical and drug quality monitoring capacity and 
is most advanced in parts of the Mekong region in South-
East Asia. This has included setting up sentinel sites for 
drug quality monitoring in several countries as well guid-
ing and assisting in the regular sampling of anti-tubercu-
losis, anti-retrovirals and anti-malarials. Working with 
governments and regulatory agencies has enabled the 
closing down of outlets, apportioning of fines, seizure of 
remaining stocks and blacklisting or delisting of outlets 
from registration, as punishments for selling or cooperat-
ing with those who sell counterfeit drugs. USP have also 
identified four areas that require urgent investment; edu-
cation and advocacy, availability of drugs, affordability of 
quality-assured drugs and enabling leadership at govern-
ment level.
’Leadership at the government level is key, we are 
struggling in all 35 countries in which we work’.
Surveillance and monitoring of drug quality at the global 
level
As a major supplier of ACT to many malaria endemic 
countries ensuring the integrity of supply chains is 
an integral interest for Global Fund (GF). Andrew 
McLoughlin, Officer of Inspector General, at the GF, 
presented on the issues related to strengthening sup-
ply chains to prevent leakage (theft)/diversion of donor-
funded anti-malarials. This leakage (theft)/diversion of 
quality assured donor-funded anti-malarials creates stock 
outs at public health facilities that result in patients being 
turned away without treatment. Stock-outs then force the 
financially able patients to seek anti-malarials from alter-
native sources, such as pharmacies and street markets, 
creating a demand whereby those vendors may unknow-
ingly sell counterfeit anti-malarials. Most of the stolen 
drugs have been identified to be sold in pharmacies and 
street markets both in the country that the anti-malarials 
were delivered to and other countries.
The WHO has established the Members State Mecha-
nism for the surveillance and monitoring of drug qual-
ity on an international scale, which was presented by 
Michael Deats (WHO). The Surveillance and Rapid Alert 
System for Substandard/Spurious/Falsely labelled/Fal-
sified/Counterfeit (SSFFC) Medical Products [32] was 
devised by the WHO to tackle the threat of contaminated 
products circulating around the globe, a problem per-
petuated as a result of increasing globalization. A number 
of countries lack technical capacity for conducting not 
just quality assurance, but more complex forensic analy-
sis, issues that the WHO is well equipped to address by 
dispatching expert teams in response to urgent requests 
for assistance made by member states. The surveillance 
and monitoring system was established to better gauge 
the scope, scale and harm caused by SSFFC medical 
products and provide technical support and alerts where 
required. In addition, a well-functioning surveillance 
system produces a validated evidence base for policy 
makers. Since 2013, the programme has engaged 113 
member states with over 920 suspect products reported 
from 83 countries. Falsified drugs remain a concern with 
WHO receiving regular reports i.e. 126 of suspected fal-
sified artemether/lumefantrine (innovator and generic 
versions), from 14 sub-Saharan African countries have 
been filed since July 2013. On investigation by the WHO, 
they were found to have less than 10 genuine medicines. 
A database logging reports of SSFFC and substandard 
drugs has been created and with relevance to falsified 
anti-malarials, 57  % of those reported so far have been 
artemisinin-based.
The types of reports and their source vary from coun-
try to country. Some are raised by national drug regula-
tory or medicines control agencies and others originate 
from an individual healthcare facility or provider. The 
most detailed reports are initiated by patients or health 
professionals however these make a small proportion of 
the total number. This highlights the need to embed the 
reporting of suspect products into national regulatory 
systems and data sharing.
Building capacity at the regional and national level
Both INTERPOL and WHO identified the importance 
of the formation of collaborative regional networks that 
shared information on the detection of a SSFFC or sub-
standard drug. Such networks enable triangulation of the 
source of the suspect product. Subsequent action against 
either the distributor or the manufacturer can then be 
taken. However, many countries do not have the judicial 
powers or capability to act. Aline Plançon from the phar-
maceutical crime programme within INTERPOL stated 
that in these instances they can assist, issuing interna-
tional arrest warrants for unscrupulous manufacturers 
based in a different country to the one in which the prod-
uct was discovered. In the last five years, there has been 
a noticeable rise in the number of warrants issued and 
subsequent criminal cases for counterfeiting. However 
complexities arise given the international nature of some 
of the major cases.
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’Having a law is one thing, having a criminal justice 
system that can manage and enforce that is some-
thing different’.
At a national level there is a need for better coordina-
tion between and across a myriad of agencies includ-
ing health and drug regulatory bodies, customs and the 
police, underpinned by appropriate and enforceable 
legislation. This requires political will and government 
engagement without which a national regulator’s author-
ity to take action against distributors or producers of 
SSFFC and substandard drugs is futile.
’The countries that do best have multi-sectorial 
stakeholder engagement, regulatory, police, customs, 
the private sector and not just manufacturers, but 
importers and retailers as well. In some parts of the 
world it’s a legal requirement that these are linked 
together. One step in prevention is encouraging lots 
of regular interaction among these groups. That 
translates into practical, on the ground benefits’.
Further considerations
An open discussion at the end of the meeting elicited 
some essential additional considerations.
Prioritizing prevention
According to the WHO, INTERPOL and USP, systems 
exist for detecting SSFFC and medical drugs. These sys-
tems track, respond to and address to some extent the 
threat of such drugs on a national, regional and interna-
tional level. However it was agreed that prevention must 
become a priority. The aforementioned multi-sectoral 
approach is imperative to preventing the proliferation 
of poor quality drugs in terms of substandard which 
will need a different approach to tackle than counterfeit 
or falsified drugs. Causes and people involved will vary. 
Engaging with Ministries of Health, empowering regula-
tory agencies and forging close ties with the private sec-
tor would vastly reduce the risk of such drugs circulating 
in a country.
Furthermore, on both a national and international scale 
pharmaceutical industries must become actively involved 
to curb the rise in SSFFC and substandard drugs. This 
includes being more transparent about their own drug 
quality data and engaging with stakeholders to build 
capacity.
’Transparency from industry about their own reports 
of drug quality is required as usually this kind of 
information is understandably kept confidential. 
However, more transparency would lessen the con-
cerns that industry is hiding information. More 
transparency will allow for more collaboration’.
Improving collaboration and coordination
Effective regulatory action is dependent on national, 
international and regional collaborations including 
timely communication, data sharing, standardized defini-
tions and methods. A multitude of drug quality screen-
ing technologies exist. There was a consensus that better 
collaboration is required in the developing and scaling up 
of these technologies. The GPHF Minilab® [33] remains a 
key component of drug quality surveillance systems. Cur-
rently many in-country laboratories have trialled alter-
native technologies but few are actually being utilized. 
Concerted effort amongst pharma and academic institu-
tions is likely to produce technologies suitable for screen-
ing drugs in the field.
The multi-disciplinarily profile of the participants 
was also emphasized, which may potentially complicate 
coordination and subsequently result in duplication of 
work. However, the range of disciplines must be allowed 
to figure more prominently to enable the formulation of 
a broader picture of the issue of drug quality. There is a 
requirement to shift the focus of drug quality from the 
technical paradigm toward a holistic model; involving 
providers, industry and regulators.
’There is scope to develop multidisciplinary 
approaches to gain a fuller picture: chemical con-
tent, epidemiology, statistics, economics, anthropol-
ogy, etc.’
Finally the need for better dialogue with the private 
sector was discussed. In low-income settings in particu-
lar, the private sector and more specifically the informal 
sector are at greatest potential risk for poor quality drugs. 
In some instances, these vendors are unaware they are 
selling such drugs and prosecuting them for doing so may 
not be the best approach to tackling the problem. The GF 
in collaboration with other donors and the WHO work to 
assure the integrity of the supply chains to reduce (stop) 
the demand resulting from the leakage (theft) of quality 
assured anti-malarials. Andrew McLaughlin and Aline 
Plançon also mentioned that the detail of their opera-
tions cannot be revealed in an open forum.
Discussions have since resulted in USP and WHO to 
embark on joint initiatives of training workshops, to pro-
duce specific training module on sampling procedures as 
well as surveillance and monitoring.
Conclusions and recommendations
A major premise of the ACTc drug quality project has 
been to establish the facts relating to the prevalence of 
ACT quality in selected countries. The systematic, and 
rigorous approaches to sampling and drug quality anal-
ysis reduced the risk of bias and produced considerable 
data that shows poor quality drugs not to be as prevalent 
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as previously reported. Whilst the numbers of falsified 
drugs were either none or less than 8  % but the sub-
standard drugs were found between 6.0 and 37  % in all 
countries where studies were conducted. In the selected 
countries, the ACTc provided a clear snapshot of the sta-
tus of the quality of ACT at the time of the surveys. How-
ever sustainable systems need to be developed to enable 
ongoing monitoring of drug quality at country level. A 
combination of approaches and methodology to sam-
pling is likely to be necessary. Given the ease and afford-
ability of convenience sampling this is likely to remain an 
important approach to detecting the presence of poor 
quality drugs in a market. Rapid field tests may be use-
ful for screening of such samples. Detection of a problem 
should trigger a representative sampling of drugs so that 
unbiased estimates of the scale of the problem can be 
generated. Quality-assured laboratory analyses of sam-
ples is essential, but the development of the necessary 
capacity in every country is a long-term ambition. In the 
meantime, the model developed by USP in south-east 
Asia, where laboratories are designated at different levels 
of capability with regional reference laboratories is grad-
ually being replicated in Africa.
Future drug quality studies should, where feasible, 
employ systematic approaches to sampling and analy-
sis and a updating of the MEDQUARG guidelines (a 
checklist of items that should be included in reports of 
medicine quality) maybe required [17]. Finally on a local, 
national, regional and international level stakeholders 
from various disciplines with an interest in drug qual-
ity must work in tandem to advocate for more attention 
to be focused on poor quality drugs. This is most cru-
cial at a national level where leadership and political will 
are two key drivers in building regulatory and technical 
capacity (testing the medicines in country to inform the 
regulator).
The key recommendations emerging from this meeting 
are:
  • A need for more systematic approaches to sampling 
and testing of drugs
  • A more holistic and multidisciplinary approach to 
drug quality research requires incorporating anthro-
pology, epidemiology, statistics and economics
  • To encourage multi-stakeholder engagement on 
a national (and global) scale to include regulatory 
agencies, customs and police supported by tangible 
and enforceable legislation
  • The need to invest and build national regulatory and 
technical capacity that is sustainable
  • To focus towards prevention of poor quality drugs 
whilst maintaining surveillance and monitoring 
activities
  • Develop a deeper understanding of the public health 
impact of substandard drugs both in terms of the 
immediate clinical implications as well as the propa-
gation of drug resistance
  • A shift in focus to the prevalence of substandard 
drugs whilst maintaining surveillance and monitor-
ing of SSFFC including substandard drugs.
Falsified ACT remains a concern, but the results of 
these studies show that there is a need to increase the 
focus on substandard ACT, which will lead to drug resist-
ance as a result of under dosing. The risk of poor quality 
ACT and falsified drugs is real and will continue to exist 
whilst unscrupulous or negligent manufacturers and dis-
tributors continue to operate. Co-operation and co-ordi-
nated action will be required to stop the scourge of poor 
quality medicines.
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